Prognostic value of p53 genetic changes in colorectal cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 593-599

  Kressner, Ulf ^a   Inganäs, Mats ^a   Byding, Sara ^a   Blikstad, Ingrid ^a   Påhlman, Lars ^a   Glimelius, Bengt ^a   Lindmark, Gudrun ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033015211     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.593     Document Type: Article

References (41)

1. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309-320, 1958
2. UICC: TNM Classification of Malignant Tumors (rev ed 4). Berlin, Germany, Springer-Verlag, 1992
3. Bosman FT: Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 31A:1216-1221, 1995
4. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
5. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
6. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 4:1009-1022, 1995
7. Fearon E, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
8. Hamelin R, Laurent-Puig GP, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterol 106:42-48, 1994
9. Goh HS, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221, 1995
10. Pricolo VE, Finkelstein SD, Wu TT, et al: Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 171:41-46, 1996
11. Smith DR, Ji CY, Goh HS: Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216-223, 1996
12. Dix B, Robbins P, Soong R, et al: The common molecular genetic alterations in Dukes B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59:747-751, 1994
13. Sjögren S, Inganäs M, Norberg T, et al: The 53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
14. Remvikos Y, Tominaga O, Hammel P, et al: Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 66:758-764, 1992
15. Sun XF, Carstensen JM, Zhang H, et al: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340:1369-1373, 1992
16. Auvinen A, Isola J, Visakorpi T, et al: Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70:293-296, 1994
17. Bosari S, Giuseppe V, Bossi P, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinoma. J Natl Cancer Inst 86:681-687, 1994
18. Bell SM, Scott N, Cross D, et al: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterol 104:57-64, 1993
19. Morrin M, Kelly M, Barret N, Delaney P: Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35:1627-1631, 1994
20. Mulder JWR, Baas IO, Polak MM, et al: Evaluation of p53 protein expression as a marker for long term prognosis in colorectal carcinoma. Br J Cancer 71:1257-1262, 1995
21. Kressner U, Lindmark G, Gerdin B, et al: Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16:951-958, 1996
22. Poller DN, Baxter KJ, Shepherd NA: p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer? Br J Cancer 75:87-93, 1997
23. Morson B, Sobin L: Histological typing of Intestinal Tumors. International Histological Classification of Tumors, No. 15, Geneva, Switzerland, World Health Organization, 1976
24. Ståhl S, Hultman T, Olsson A, et al: Solid phase DNA sequencing using the biotin-avidin system. Nucleic Acids Res 16:3025-3038, 1988
25. Lagerkvist A, Stewart J, Lagerström-Fermér M, et al: Manifold sequencing: Efficient processing of large sets of sequencing reactions. Proc Natl Acad Sci USA 91:2245-2249, 1994
26. Kressner U, Lindmark G, Gerdin B, et al: Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res 15:2755-2762, 1995
27. Kressner U, Glimelius B, Bergström R, et al: Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848-1851, 1998
28. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B34:187-220, 1972
29. Peto R, Pike M, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observations of each patient: II. Analysis and examples. Br J Surg 35:1-39, 1977
30. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1992
31. Lane D: p53 and human cancers. Br Med Bull 50:582-599, 1994
32. Costa A, Marasca R, Valentinis B, et al: p53 gene missense mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176:45-53, 1995
33. Dix B, Robbins P, Carello A, et al: Comparison of p53 gene mutation and protein overexpression in colorectal carcinoma. Br J Cancer 70:585-590, 1994
34. Haupt Y, Maya R, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296-299, 1997
35. Kubbutat M, Jones S, Vousden K: Regulation of p53 stability by Mdm2. Nature 387:299-303, 1997
36. Baas IO, Mulder JWR, Offerhaus GJ, et al: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 72:5-12, 1994
37. Cripps K, Purdie CA, Carder PJ, et al: A study of p53 protein versus point mutation in colorectal cancer. Oncogene 9:2739-2743, 1994
38. Brett MC, Pickard M, Green B, et al: p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 22:182-185, 1996
39. Lowe S, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
40. McIlwrath AJ, Vasey PA, Ross GM, et al: Cell cycle arrest and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 54:3718-3722, 1994
41. Mashal RD, Koontz J, Sklar J: Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nat Gen 9:177-183, 1995